2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

SARS 3CL protease inhibitor

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

3

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17007
    Saquinavir
    5+ Cited Publications

    Ro 31-8959

    		 HIV HIV Protease SARS-CoV Infection Cancer
    Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.36 μM.
    Saquinavir
  • HY-90001
    Ritonavir
    20+ Cited Publications

    ABT 538; RTV

    		 HIV Protease HIV SARS-CoV Apoptosis Infection Cancer
    Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir
  • HY-150691
    SARS 3CLpro-IN-1

    		SARS-CoV Cancer
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .
    SARS 3CLpro-IN-1
  • HY-162414
    SARS-CoV-2-IN-84

    		SARS-CoV Infection
    SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ) .
    SARS-CoV-2-IN-84
  • HY-147020
    Coronastat

    NK01-63

    		 SARS-CoV Infection
    Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .
    Coronastat
  • HY-157778
    MK-7845

    		SARS-CoV Infection
    MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM .
    MK-7845
  • HY-144833
    SARS-CoV-2 3CLpro-IN-1

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
    SARS-CoV-2 3CLpro-IN-1
  • HY-152009
    SARS-CoV-2 3CLpro-IN-7

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM .
    SARS-CoV-2 3CLpro-IN-7
  • HY-152005
    SARS-CoV-2 3CLpro-IN-6

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-6
  • HY-144062
    INSCoV-614(1B)

    		SARS-CoV Infection
    INSCoV-614(1B) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-614(1B)
  • HY-111074
    DB12055

    MK-0767 analog

    		 SARS-CoV Infection Metabolic Disease
    DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus .
    DB12055
  • HY-143216
    Ensitrelvir
    5+ Cited Publications

    S-217622

    		 SARS-CoV Virus Protease Infection
    Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) .
    Ensitrelvir
  • HY-143216A
    Ensitrelvir fumarate
    5+ Cited Publications

    S-217622 fumarate

    		 SARS-CoV Virus Protease Infection
    Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) .
    Ensitrelvir fumarate
  • HY-137048
    PF-00835231
    2 Publications Verification

    		 SARS-CoV HIV HCV Infection
    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL pro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models .
    PF-00835231
  • HY-144061
    INSCoV-601I(1)

    		SARS-CoV Infection
    INSCoV-601I(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-601I(1)
  • HY-144063
    INSCoV-600K(1)

    		SARS-CoV Infection
    INSCoV-600K(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-600K(1)
  • HY-17430
    Amprenavir
    5+ Cited Publications

    VX-478

    		 HIV HIV Protease SARS-CoV Infection Cancer
    Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.09 μM.
    Amprenavir
  • HY-146998
    SARS-CoV-2 3CLpro-IN-2

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
    SARS-CoV-2 3CLpro-IN-2
  • HY-149264
    SARS-CoV-2 3CLpro-IN-13

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .
    SARS-CoV-2 3CLpro-IN-13
  • HY-153228
    Pomotrelvir

    PBI-0451

    		 SARS-CoV Infection
    Pomotrelvir (PBI-0451) is a selective, orally active SARS-CoV-2 3CL protease inhibitor. Pomotrelvir has antiviral activity and can be used in the research of novel coronavirus (COVID-19) .
    Pomotrelvir
  • HY-17634
    Glecaprevir
    5 Publications Verification

    ABT-493

    		 HCV HCV Protease SARS-CoV Infection
    Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 4.09 μM .
    Glecaprevir
  • HY-151535
    SARS-CoV-2 3CLpro-IN-5

    		SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-5
  • HY-138687
    Nirmatrelvir
    Maximum Cited Publications
    73 Publications Verification

    PF-07321332

    		 SARS-CoV Infection Inflammation/Immunology
    Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
    Nirmatrelvir
  • HY-17007R
    Saquinavir (Standard)

    		HIV HIV Protease SARS-CoV Infection Cancer
    Saquinavir (Standard) is the analytical standard of Saquinavir. This product is intended for research and analytical applications. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.36 μM.
    Saquinavir (Standard)
  • HY-W653853
    Ritonavir-13C3

    ABT 538-13C3; RTV-13C3

    		 Isotope-Labeled Compounds Apoptosis SARS-CoV HIV Protease HIV Cancer
    Ritonavir- 13C3 is 13C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM .
    Ritonavir-13C3
  • HY-90001R
    Ritonavir (Standard)

    ABT 538 (Standard); RTV (Standard)

    		 HIV Protease HIV SARS-CoV Apoptosis Infection Cancer
    Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir (Standard)
  • HY-10300
    Narlaprevir
    4 Publications Verification

    SCH 900518

    		 HCV HCV Protease SARS-CoV Infection
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM .
    Narlaprevir
  • HY-14434
    Asunaprevir
    35+ Cited Publications

    BMS-650032

    		 HCV HCV Protease SARS-CoV Infection
    Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL pro activity .
    Asunaprevir
  • HY-149767
    CMX990

    		SARS-CoV Infection
    CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties .
    CMX990
  • HY-156651
    Zevotrelvir

    EDP-235

    		 SARS-CoV Infection
    Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC50 ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections .
    Zevotrelvir
  • HY-15148
    Tipranavir
    5+ Cited Publications

    PNU-140690

    		 HIV Protease HIV SARS-CoV Infection
    Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity .
    Tipranavir
  • HY-W760546
    SARS-CoV-2 3CLpro-IN-15

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
    SARS-CoV-2 3CLpro-IN-15
  • HY-145276
    SARS-CoV-2-IN-10

    		SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-10
  • HY-145277
    SARS-CoV-2-IN-11

    		SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-11
  • HY-10237
    Boceprevir
    30+ Cited Publications

    EBP 520; SCH 503034

    		 HCV Protease HCV SARS-CoV Infection
    Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
    Boceprevir
  • HY-17367
    Atazanavir
    10+ Cited Publications

    BMS-232632

    		 HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 3.49 μM .
    Atazanavir
  • HY-17367A
    Atazanavir sulfate
    10+ Cited Publications

    BMS-232632 sulfate

    		 HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 3.49 μM .
    Atazanavir sulfate
  • HY-138687R
    Nirmatrelvir (Standard)

    		SARS-CoV Infection Inflammation/Immunology
    Nirmatrelvir (Standard) is the analytical standard of Nirmatrelvir. This product is intended for research and analytical applications. Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
    Nirmatrelvir (Standard)
  • HY-B0689
    Indinavir

    MK-639 free base; L-735524 free base

    		 HIV HIV Protease Apoptosis MMP SARS-CoV Inflammation/Immunology Cancer
    Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL pro inhibitor .
    Indinavir
  • HY-B0689A
    Indinavir sulfate
    5+ Cited Publications

    MK-639; L735524

    		 HIV HIV Protease SARS-CoV Apoptosis MMP Infection Cancer
    Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CL pro inhibitor .
    Indinavir sulfate
  • HY-10235
    Telaprevir
    40+ Cited Publications

    VX-950

    		 HCV Protease HCV SARS-CoV Infection
    Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL pro activity .
    Telaprevir
  • HY-14588
    Lopinavir
    10+ Cited Publications

    ABT-378

    		 HIV HIV Protease SARS-CoV Infection Cancer
    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 14.2 μM .
    Lopinavir
  • HY-15148R
    Tipranavir (Standard)

    		HIV Protease HIV SARS-CoV Infection
    Tipranavir (Standard) is the analytical standard of Tipranavir. This product is intended for research and analytical applications. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity .
    Tipranavir (Standard)
  • HY-17367R
    Atazanavir (Standard)

    		HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 3.49 μM .
    Atazanavir (Standard)
  • HY-B0689B
    Indinavir sulfate ethanolate

    MK-639 ethanolate; L735524 ethanolate

    		 Apoptosis MMP HIV HIV Protease SARS-CoV Infection Cancer
    Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CL pro inhibitor .
    Indinavir sulfate ethanolate
  • HY-10237R
    Boceprevir (Standard)

    		HCV Protease HCV SARS-CoV Infection
    Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
    Boceprevir (Standard)
  • HY-14588R
    Lopinavir (Standard)

    ABT-378 (Standard)

    		 HIV HIV Protease SARS-CoV Infection Cancer
    Lopinavir (Standard) is the analytical standard of Lopinavir. This product is intended for research and analytical applications. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 14.2 μM .
    Lopinavir (Standard)
  • HY-15298
    Grazoprevir
    25+ Cited Publications

    MK-5172

    		 HCV Protease HCV SARS-CoV Infection
    Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir
  • HY-15298A
    Grazoprevir potassium salt
    25+ Cited Publications

    MK-5172 potassium salt

    		 HCV HCV Protease SARS-CoV Infection
    Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir potassium salt
  • HY-15298C
    Grazoprevir sodium salt

    MK-5172 sodium salt

    		 HCV HCV Protease SARS-CoV Infection
    Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir sodium salt

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: